56. ベーチェット病 Disease details / Clinical trials / Drug dev / DR info

Adalimumab
   AZIENDA OSPEDALIERO-UNIVERSITARIA PISANA
      2017   Phase 3   EUCTR2017-000845-39-IT   Italy
   AbbVie (prior sponsor, Abbott)
      2010   Phase 3   NCT01243671   Japan
   Assistance Publique Hôpitaux de Paris / DRCI
      2022   Phase 2   EUCTR2022-001316-26-FR   France
   State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-Sen University
      2020   Phase 4   ChiCTR1900027147   China
   The First Affiliated Hospital of Chongqing Medical University
      2020   Phase 4   ChiCTR2000031637   China
   The First Affiliated Hospital, College of Medicine, Zhejiang University
      2021   Phase 4   ChiCTR2100045463   China
AIN457
   Novartis Farmacéutica, S.A.
      2010   -   EUCTR2009-013901-33-ES   Austria;France;Germany;Greece;Spain
      2009   Phase 3   EUCTR2009-011237-27-ES   Austria;France;Germany;Greece;Hungary;Italy;Spain
   Novartis Pharma Services AG
      2010   -   EUCTR2009-013901-33-GR   Austria;France;Germany;Greece;Spain
      2010   -   EUCTR2009-013901-33-FR   Austria;France;Germany;Greece;Spain
      2010   -   EUCTR2009-013901-33-DE   Austria;France;Germany;Greece;Spain
      2009   -   EUCTR2009-013901-33-AT   Austria;France;Germany;Greece;Spain
      2009   -   EUCTR2009-011237-27-DE   Austria;France;Germany;Greece;Hungary;Italy;Spain
      2009   -   EUCTR2009-011237-27-AT   Austria;France;Germany;Greece;Hungary;Italy;Spain
   Novartis Pharma Services Ag
      2009   -   EUCTR2009-011237-27-HU   Austria;France;Germany;Greece;Hungary;Italy;Spain
      2009   -   EUCTR2009-011237-27-GR   Austria;France;Germany;Greece;Hungary;Italy;Spain
      2009   -   EUCTR2009-011237-27-FR   Austria;France;Germany;Greece;Hungary;Italy;Spain
   Novartis Pharmaceuticals
      2009   Phase 3   NCT00995709   Austria;Brazil;Egypt;France;Germany;Greece;Hong Kong;Hungary;India;Israel;Italy;Jordan;Korea, Republic of;Saudi Arabia;Singapore;Spain;Switzerland;Taiwan;Tunisia;Turkey;United States
Allogeneic stem cell transplant
   Northwestern University
      2003   Phase 1   NCT00278512   United States
Alpha interferon
   The University of Liverpool
      2016   Phase 3   EUCTR2014-005390-36-GB   United Kingdom
AMG 407
   AMGEN INC.
      2023   Phase 3   EUCTR2022-003024-41-IT   France;Greece;Israel;Italy;Spain;Switzerland;Turkey;United Kingdom
      2021   Phase 3   EUCTR2019-002787-27-IT   France;Greece;Israel;Italy;Netherlands;Switzerland
   Amgen Inc
      2023   Phase 3   EUCTR2022-003024-41-FR   France;Greece;Israel;Italy;Spain;Switzerland;Turkey;United Kingdom
      2023   Phase 3   EUCTR2022-003024-41-ES   France;Greece;Israel;Italy;Spain;Switzerland;Turkey;United Kingdom
      -   Phase 3   EUCTR2022-003024-41-GR   France;Greece;Israel;Italy;Spain;Switzerland;Turkey;United Kingdom
AMG-407
   Amgen Inc.
      2021   Phase 3   EUCTR2019-002787-27-GR   France;Greece;Israel;Italy;Netherlands;Switzerland
      2021   Phase 3   EUCTR2019-002787-27-FR   France;Greece;Israel;Italy;Netherlands;Switzerland
      -   Phase 3   EUCTR2019-002787-27-NL   France;Greece;Israel;Italy;Netherlands;Spain;Switzerland;United Kingdom
AMG407
   AMGEN INC.
      2021   Phase 3   EUCTR2019-002787-27-IT   France;Greece;Israel;Italy;Netherlands;Switzerland
   Amgen Inc.
      2021   Phase 3   EUCTR2019-002787-27-GR   France;Greece;Israel;Italy;Netherlands;Switzerland
      2021   Phase 3   EUCTR2019-002787-27-FR   France;Greece;Israel;Italy;Netherlands;Switzerland
      -   Phase 3   EUCTR2019-002787-27-NL   France;Greece;Israel;Italy;Netherlands;Spain;Switzerland;United Kingdom
Anakinra
   National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
      2011   Phase 1/Phase 2   NCT01441076   United States
Apremilast
   AMGEN INC.
      2021   Phase 3   EUCTR2019-002787-27-IT   France;Greece;Israel;Italy;Netherlands;Switzerland
   Amgen
      2023   Phase 3   NCT05767047   Greece;Israel;Spain;Turkey
      2021   Phase 3   NCT04528082   France;Greece;Israel;Italy;Spain;Switzerland;Turkey;United Kingdom
      2014   Phase 3   NCT02307513   France;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Lebanon;Turkey;United States
   Amgen Inc.
      2015   Phase 3   EUCTR2014-002108-25-DE   France;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Turkey;United States
   Celgene Corporation
      2016   Phase 3   EUCTR2014-002108-25-GR   France;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Turkey;United States
      2015   Phase 3   EUCTR2014-002108-25-IT   France;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Turkey;United States
Apremilast 10 MG
   Amgen Inc.
      2021   Phase 3   EUCTR2019-002787-27-GR   France;Greece;Israel;Italy;Netherlands;Switzerland
      2021   Phase 3   EUCTR2019-002787-27-FR   France;Greece;Israel;Italy;Netherlands;Switzerland
      -   Phase 3   EUCTR2019-002787-27-NL   France;Greece;Israel;Italy;Netherlands;Spain;Switzerland;United Kingdom
Apremilast 20 MG
   AMGEN INC.
      2023   Phase 3   EUCTR2022-003024-41-IT   France;Greece;Israel;Italy;Spain;Switzerland;Turkey;United Kingdom
   Amgen Inc
      2023   Phase 3   EUCTR2022-003024-41-FR   France;Greece;Israel;Italy;Spain;Switzerland;Turkey;United Kingdom
      2023   Phase 3   EUCTR2022-003024-41-ES   France;Greece;Israel;Italy;Spain;Switzerland;Turkey;United Kingdom
      -   Phase 3   EUCTR2022-003024-41-GR   France;Greece;Israel;Italy;Spain;Switzerland;Turkey;United Kingdom
   Amgen Inc.
      2021   Phase 3   EUCTR2019-002787-27-GR   France;Greece;Israel;Italy;Netherlands;Switzerland
      2021   Phase 3   EUCTR2019-002787-27-FR   France;Greece;Israel;Italy;Netherlands;Switzerland
      -   Phase 3   EUCTR2019-002787-27-NL   France;Greece;Israel;Italy;Netherlands;Spain;Switzerland;United Kingdom
Apremilast 30 MG
   AMGEN INC.
      2023   Phase 3   EUCTR2022-003024-41-IT   France;Greece;Israel;Italy;Spain;Switzerland;Turkey;United Kingdom
   Amgen Inc
      2023   Phase 3   EUCTR2022-003024-41-FR   France;Greece;Israel;Italy;Spain;Switzerland;Turkey;United Kingdom
      2023   Phase 3   EUCTR2022-003024-41-ES   France;Greece;Israel;Italy;Spain;Switzerland;Turkey;United Kingdom
      -   Phase 3   EUCTR2022-003024-41-GR   France;Greece;Israel;Italy;Spain;Switzerland;Turkey;United Kingdom
   Amgen Inc.
      2021   Phase 3   EUCTR2019-002787-27-GR   France;Greece;Israel;Italy;Netherlands;Switzerland
      2021   Phase 3   EUCTR2019-002787-27-FR   France;Greece;Israel;Italy;Netherlands;Switzerland
      -   Phase 3   EUCTR2019-002787-27-NL   France;Greece;Israel;Italy;Netherlands;Spain;Switzerland;United Kingdom
Autologous stem cell transplant
   Northwestern University
      2003   Phase 1   NCT00278512   United States
Autologous stem cell transplantation
   Tehran University of Medical Sciences
      2007   Phase 1   NCT00550498   Iran, Islamic Republic of
BCMA-CD19 CAR-T therapy
   Peking University People's Hospital
      2024   Phase 2   NCT06794008   China
Betamethasone mouthwash
   Cairo University
      2023   Phase 1/Phase 2   NCT06084624   -
Biobanking with genetic analysis
   University Hospital, Lille
      2020   -   NCT04334031   France
Canakinumab
   Novartis Pharmaceuticals
      2016   Phase 2   NCT02756650   Turkey
   University Hospital of Tübingen
      2011   Phase 3   EUCTR2010-024152-29-DE   Germany
CC-10004
   Amgen Inc.
      2015   Phase 3   EUCTR2014-002108-25-DE   France;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Turkey;United States
   Celgene Corporation
      2016   Phase 3   EUCTR2014-002108-25-GR   France;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Turkey;United States
      2015   Phase 3   EUCTR2014-002108-25-IT   France;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Turkey;United States
Colchicine
   Ipekyolu Ilac Ltd. Sti
      2019   Phase 2   NCT03888846   Turkey
   Tehran University of Medical Sciences
      2002   Phase 2   NCT00700297   Iran, Islamic Republic of
Crohn'S disease
   The Affiliated Hospital of Qingdao University
      2023   -   ChiCTR2300073620   China
Cyclophosphamide
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
      -   Phase 2   EUCTR2017-002264-41-FR   France
   Assistance Publique - Hôpitaux de Paris
      2018   Phase 3   NCT03371095   France
Cyclosporin A
   University Hospital Tuebingen
      2004   Phase 3   NCT00167583   Germany
Cyclosporine
   The First Affiliated Hospital of Chongqing Medical University
      2020   Phase 4   ChiCTR2000031637   China
   Yokohama City University Hospital
      2017   -   JPRN-UMIN000025451   Japan
Cyclosporine pill
   Peking Union Medical College Hospital
      2017   Phase 3   NCT03209219   China
Cytotoxic combination
   Tehran University of Medical Sciences
      2006   Phase 2   NCT00664599   Iran, Islamic Republic of
Daclizumab
   National Eye Institute (NEI)
      1999   Phase 2   NCT00001865   United States
Dextrose
   Tehran University of Medical Sciences
      2010   Phase 4   NCT01306955   Iran, Islamic Republic of
Diode laser 980NM&100 mwatt
   Cairo University
      2019   -   NCT03771768   -
Dusquetide
   Soligenix
      2024   Phase 2   NCT06386744   Turkey
Entecavir
   Saitama Medical University
      2016   -   JPRN-UMIN000020029   Japan
Etanercept, methotrexate, prednisolone
   Tehran University of Medical Sciences
      2010   -   NCT00931957   Iran, Islamic Republic of
Filgotinib
   UMC Utrecht
      2024   Phase 2   NCT06285539   Netherlands
Flucinolone acetonide
   Asan Medical Center
      2008   Phase 4   NCT00720928   Korea, Republic of
Gevokizumab
   INSTITUT DE RECHERCHES INTERNATIONALES SERVIER
      2012   -   EUCTR2012-001125-27-IT   Brazil;China;Germany;Greece;Hong Kong;India;Italy;Korea, Republic of;Portugal;Russian Federation;Saudi Arabia;Spain;Tunisia;Turkey;United Kingdom
   Institut de Recherches Internationales Servier
      2013   Phase 3   EUCTR2012-001125-27-PT   Brazil;China;France;Germany;Greece;Hong Kong;India;Italy;Korea, Republic of;Portugal;Russian Federation;Saudi Arabia;Spain;Tunisia;Turkey;United Kingdom
      2013   Phase 3   EUCTR2012-001125-27-GB   Brazil;China;France;Germany;Greece;Hong Kong;India;Italy;Korea, Republic of;Portugal;Russian Federation;Saudi Arabia;Spain;Tunisia;Turkey;United Kingdom
      2012   -   EUCTR2012-001125-27-GR   Brazil;China;France;Germany;Greece;Hong Kong;India;Italy;Korea, Republic of;Portugal;Russian Federation;Saudi Arabia;Spain;Tunisia;Turkey;United Kingdom
      2012   -   EUCTR2012-001125-27-DE   Brazil;China;France;Germany;Greece;Hong Kong;India;Italy;Korea, Republic of;Portugal;Russian Federation;Saudi Arabia;Spain;Tunisia;Turkey;United Kingdom
   XOMA (US) LLC
      2014   Phase 3   NCT02258867   United States
Golimumab
   Wenjie Zheng
      2020   Phase 2   NCT04218565   China
GSK1070806
   Cambridge University Hospitals NHS Foundation Trust
      2018   Phase 2   NCT03522662   United Kingdom
Hemay005
   Ganzhou Hemay Pharmaceutical Co., Ltd
      2023   Phase 3   NCT06145893   China
   Tianjin Hemay Pharmaceutical Co., Ltd
      2020   Phase 2   NCT04609397   China
Herpes zoster vaccine
   University of Sao Paulo General Hospital
      2023   Phase 4   NCT05879419   Brazil
Humira
   Sohag University
      2022   -   NCT05683626   Egypt
Humira - 40 MG soluzione iniettabile USO sottocutaneo 1 siringa preriempita 0.8 ML + 1 tampone imbevuto DI alcol IN UN blister
   AZIENDA OSPEDALIERO-UNIVERSITARIA PISANA
      2017   Phase 3   EUCTR2017-000845-39-IT   Italy
Humira 40MG, solution injectable EN stylo PRérempli
   Assistance Publique Hôpitaux de Paris / DRCI
      2022   Phase 2   EUCTR2022-001316-26-FR   France
Hydroxychloroquine
   Assiut University
      2018   -   NCT04022421   Egypt
Ilaris
   University Hospital of Tübingen
      2011   Phase 3   EUCTR2010-024152-29-DE   Germany
Inflectra - 100 MG - polvere PER concentrato PER soluzione PER infusione - USO endovenoso - flaconcino (vetro) - 1 flaconcino
   AZIENDA OSPEDALIERO-UNIVERSITARIA PISANA
      2017   Phase 3   EUCTR2017-000845-39-IT   Italy
Infliximab
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
      -   Phase 2   EUCTR2017-002264-41-FR   France
   AZIENDA OSPEDALIERO-UNIVERSITARIA PISANA
      2017   Phase 3   EUCTR2017-000845-39-IT   Italy
   Assistance Publique - Hôpitaux de Paris
      2018   Phase 3   NCT03371095   France
   Janssen Korea, Ltd., Korea
      2015   Phase 3   NCT02505568   Korea, Republic of
   The University of Liverpool
      2016   Phase 3   EUCTR2014-005390-36-GB   United Kingdom
   Yokohama City University Hospital
      2017   -   JPRN-UMIN000025451   Japan
Interferon ALFA-2A
   Peking Union Medical College Hospital
      2017   Phase 3   NCT03209219   China
Interferon alpha-2A
   The First Affiliated Hospital of Chongqing Medical University
      2020   Phase 4   ChiCTR2000031637   China
Interferon-alpha2A
   University Hospital Tuebingen
      2004   Phase 3   NCT00167583   Germany
Interleukin 2
   Assistance Publique - Hôpitaux de Paris
      2014   Phase 2   NCT01988506   France
Intravitreal infliximab
   Cairo University
      2013   Phase 1/Phase 2   NCT02620618   -
J1081
   The University of Liverpool
      2016   Phase 3   EUCTR2014-005390-36-GB   United Kingdom
LOW-dose IL-2
   HeJing
      2021   Phase 2   NCT04065672   China
Medrol - 4 MG compresse 30 compresse
   AZIENDA OSPEDALIERO-UNIVERSITARIA PISANA
      2017   Phase 3   EUCTR2017-000845-39-IT   Italy
Methylorednisolone
   Tehran University of Medical Sciences
      2010   Phase 4   NCT01306955   Iran, Islamic Republic of
Metilprednisolone sodio succinato
   AZIENDA OSPEDALIERO-UNIVERSITARIA PISANA
      2017   Phase 3   EUCTR2017-000845-39-IT   Italy
MMF discontinuation
   University of Sao Paulo General Hospital
      2023   Phase 4   NCT05879419   Brazil
MMF maintain
   University of Sao Paulo General Hospital
      2023   Phase 4   NCT05879419   Brazil
MTX discontinuation
   University of Sao Paulo General Hospital
      2023   Phase 4   NCT05879419   Brazil
MTX maintain
   University of Sao Paulo General Hospital
      2023   Phase 4   NCT05879419   Brazil
Otezla
   Amgen Inc
      2023   Phase 3   EUCTR2022-003024-41-FR   France;Greece;Israel;Italy;Spain;Switzerland;Turkey;United Kingdom
      2023   Phase 3   EUCTR2022-003024-41-ES   France;Greece;Israel;Italy;Spain;Switzerland;Turkey;United Kingdom
      -   Phase 3   EUCTR2022-003024-41-GR   France;Greece;Israel;Italy;Spain;Switzerland;Turkey;United Kingdom
   Amgen Inc.
      2021   Phase 3   EUCTR2019-002787-27-GR   France;Greece;Israel;Italy;Netherlands;Switzerland
      2021   Phase 3   EUCTR2019-002787-27-FR   France;Greece;Israel;Italy;Netherlands;Switzerland
      2015   Phase 3   EUCTR2014-002108-25-DE   France;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Turkey;United States
      -   Phase 3   EUCTR2019-002787-27-NL   France;Greece;Israel;Italy;Netherlands;Spain;Switzerland;United Kingdom
Otezla - 10 MG + 20 MG + 30 MG compressa rivestita CON film USO orale - blister (PVC/ALU) IN UN astuccio - 4 compresse DA 10 MG + 4 compresse DA 20 MG +19 compresse DA 30 MG
   AMGEN INC.
      2023   Phase 3   EUCTR2022-003024-41-IT   France;Greece;Israel;Italy;Spain;Switzerland;Turkey;United Kingdom
      2021   Phase 3   EUCTR2019-002787-27-IT   France;Greece;Israel;Italy;Netherlands;Switzerland
Pentoxifylline
   Ipekyolu Ilac Ltd. Sti
      2019   Phase 2   NCT03888846   Turkey
   Silk Road Therapies, Inc.
      2024   Phase 2   NCT04186559   United States
Prednisolone
   Castle Study Group
      2013   -   JPRN-UMIN000012469   Japan
Rebamipide mouthwash
   Cairo University
      2023   Phase 1/Phase 2   NCT06084624   -
Remicade
   The University of Liverpool
      2016   Phase 3   EUCTR2014-005390-36-GB   United Kingdom
Remicade 100 MG
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
      -   Phase 2   EUCTR2017-002264-41-FR   France
Rituximab
   Tehran University of Medical Sciences
      2006   Phase 2   NCT00664599   Iran, Islamic Republic of
Rivaroxaban plus immunosupression
   Marmara University
      2025   Phase 3   NCT06925698   Turkey
Roactemra 162 MG solution injectable EN seringue PRéremplie
   Assistance Publique Hôpitaux de Paris / DRCI
      2022   Phase 2   EUCTR2022-001316-26-FR   France
Roferon-A 3MIU
   The University of Liverpool
      2016   Phase 3   EUCTR2014-005390-36-GB   United Kingdom
Roferon-A, 3MIU
   The University of Liverpool
      2016   Phase 3   EUCTR2014-005390-36-GB   United Kingdom
Roferon-A, 4.5MIU
   The University of Liverpool
      2016   Phase 3   EUCTR2014-005390-36-GB   United Kingdom
Roferon-A, 6MIU
   The University of Liverpool
      2016   Phase 3   EUCTR2014-005390-36-GB   United Kingdom
Rosuvastatin calcium 40MG
   University of Alexandria
      2010   -   NCT04328064   -
S78989
   INSTITUT DE RECHERCHES INTERNATIONALES SERVIER
      2012   -   EUCTR2012-001125-27-IT   Brazil;China;Germany;Greece;Hong Kong;India;Italy;Korea, Republic of;Portugal;Russian Federation;Saudi Arabia;Spain;Tunisia;Turkey;United Kingdom
   Institut de Recherches Internationales Servier
      2013   Phase 3   EUCTR2012-001125-27-PT   Brazil;China;France;Germany;Greece;Hong Kong;India;Italy;Korea, Republic of;Portugal;Russian Federation;Saudi Arabia;Spain;Tunisia;Turkey;United Kingdom
      2013   Phase 3   EUCTR2012-001125-27-GB   Brazil;China;France;Germany;Greece;Hong Kong;India;Italy;Korea, Republic of;Portugal;Russian Federation;Saudi Arabia;Spain;Tunisia;Turkey;United Kingdom
      2012   -   EUCTR2012-001125-27-GR   Brazil;China;France;Germany;Greece;Hong Kong;India;Italy;Korea, Republic of;Portugal;Russian Federation;Saudi Arabia;Spain;Tunisia;Turkey;United Kingdom
      2012   -   EUCTR2012-001125-27-DE   Brazil;China;France;Germany;Greece;Hong Kong;India;Italy;Korea, Republic of;Portugal;Russian Federation;Saudi Arabia;Spain;Tunisia;Turkey;United Kingdom
Serum levels OF angiogenin, bfgf, vegf
   Turkish Ophthalmology Society
      2011   -   NCT01720628   Turkey
SF-12 questionnaire
   University Hospital, Lille
      2020   -   NCT04334031   France
Solu medrol - 40 MG/ML polvere E solvente PER soluzione iniettabile 1 flacone A doppia camera DA 40 MG/ML
   AZIENDA OSPEDALIERO-UNIVERSITARIA PISANA
      2017   Phase 3   EUCTR2017-000845-39-IT   Italy
Solu medrol - 500 MG/8 ML polvere E solvente PER soluzione iniettabile 1 flacone DI polvere DA 500 MG+ fiala solvente DA 8 ML
   AZIENDA OSPEDALIERO-UNIVERSITARIA PISANA
      2017   Phase 3   EUCTR2017-000845-39-IT   Italy
Stelara
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
      2015   Phase 2   EUCTR2015-002190-37-FR   France
Subcutaneous ustekinumab
   Assistance Publique - Hôpitaux de Paris
      2017   Phase 2   NCT02648581   France
TA-650
   Mitsubishi Tanabe Pharma Corporation
      2012   Phase 3   NCT01532570   Japan
Tacrolimus ointment
   Assiut University
      2019   -   NCT05032248   Egypt
Thalidomide
   Shanghai Traditional Chinese Medicine Hospital
      2021   Phase 0   ChiCTR2000037172   China
Tocilizumab
   Assistance Publique Hôpitaux de Paris / DRCI
      2022   Phase 2   EUCTR2022-001316-26-FR   France
   Wenjie Zheng
      2018   Phase 2   NCT03554161   China
Triamcinolone acetonide
   Cairo University
      2019   -   NCT03771768   -
Ustekinumab
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
      2015   Phase 2   EUCTR2015-002190-37-FR   France
Water
   Tehran University of Medical Sciences
      2010   Phase 4   NCT01306955   Iran, Islamic Republic of
Xoma 052
   INSTITUT DE RECHERCHES INTERNATIONALES SERVIER
      2012   -   EUCTR2012-001125-27-IT   Brazil;China;Germany;Greece;Hong Kong;India;Italy;Korea, Republic of;Portugal;Russian Federation;Saudi Arabia;Spain;Tunisia;Turkey;United Kingdom
   Institut de Recherches Internationales Servier
      2013   Phase 3   EUCTR2012-001125-27-PT   Brazil;China;France;Germany;Greece;Hong Kong;India;Italy;Korea, Republic of;Portugal;Russian Federation;Saudi Arabia;Spain;Tunisia;Turkey;United Kingdom
      2013   Phase 3   EUCTR2012-001125-27-GB   Brazil;China;France;Germany;Greece;Hong Kong;India;Italy;Korea, Republic of;Portugal;Russian Federation;Saudi Arabia;Spain;Tunisia;Turkey;United Kingdom
      2012   -   EUCTR2012-001125-27-GR   Brazil;China;France;Germany;Greece;Hong Kong;India;Italy;Korea, Republic of;Portugal;Russian Federation;Saudi Arabia;Spain;Tunisia;Turkey;United Kingdom
      2012   -   EUCTR2012-001125-27-DE   Brazil;China;France;Germany;Greece;Hong Kong;India;Italy;Korea, Republic of;Portugal;Russian Federation;Saudi Arabia;Spain;Tunisia;Turkey;United Kingdom
   National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
      2010   Phase 1/Phase 2   NCT01211977   United States